Endocrine responses to critical illness: Novel insights and therapeutic implications

Journal of Clinical Endocrinology and Metabolism

Volumn 99, Issue 5, 2014, Pages 1569-1582

  Boonen, Eva ^a   Van Den Berghe, Greet ^a  

^a LABORATORY OF MOLECULAR AND CELLULAR SIGNALING   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOTROPIN; GLUCOCORTICOID; HYDROCORTISONE; INTERLEUKIN 1; INTERLEUKIN 6; LIOTHYRONINE; PROTIRELIN; THYROTROPIN; THYROXINE; TUMOR NECROSIS FACTOR ALPHA;

ADRENAL CORTEX INSUFFICIENCY; ADRENAL INSUFFICIENCY; ARTICLE; CONTINUOUS INFUSION; CRITICAL ILLNESS; CYTOKINE RELEASE; GLYCEMIC CONTROL; HORMONE RELEASE; HUMAN; HYDROCORTISONE BLOOD LEVEL; HYPERGLYCEMIA; HYPERTHYROIDISM; HYPOPHYSIS THYROID SYSTEM; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; HYPOTHYROIDISM; INTENSIVE CARE; LIOTHYRONINE BLOOD LEVEL; LOADING DRUG DOSE; NONHUMAN; PARENTERAL NUTRITION; PRIORITY JOURNAL; SEPSIS; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; THYROTROPIN BLOOD LEVEL; THYROXINE BLOOD LEVEL;

CRITICAL ILLNESS; HUMANS; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; PITUITARY-ADRENAL SYSTEM; THYROID GLAND;

EID: 84899945830     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2013-4115     Document Type: Article

References (127)

1. Casaer MP, Langouche L, Coudyzer W, et al. I mpact of early parenteral nutrition on muscle and adipose tissue compartments during critical illness. Crit Care Med. 2013;41:2298-2309.
2. Puthucheary ZA, Rawal J, McPhail M, et al. Acute skeletal muscle wasting in critical illness. JAMA. 2013;310:1591-1600.
3. Villet S, Chiolero RL, Bollmann MD, et al. Negative impact of hypocaloric feeding and energy balance on clinical outcome in ICU patients. Clin Nutr. 2005;24:502-509.
4. Hermans G, Casaer MP, Clerckx B, et al. Effect of tolerating macronutrient deficit on the development of intensive-care unit acquired weakness: a suban alysis of the EPaNIC trial. Lancet Respir Med. 2013;1:621-629.
5. Vanhorebeek I, Gunst J, Derde S, et al. Insufficient activation of autophagy allows cellular damage to accumulate in critically ill patients. J Clin Endocrinol Metab. 2011;96:E633-E645.
6. Chopra IJ, Huang TS, Beredo A, Solomon DH, Chua Teco GN, M ead JF. Evidence for an inhibitor of extrathyroidal conversion of thyroxine to 3,5,3-triiodothyronine in sera of patients with nonthyroidal illnesses. J Clin Endocrinol Metab. 1985;60:666-672.
7. Micha laki M, Vagenakis AG, Makri M, Kalfarentzos F, Kyriazopoulou V. Dissociation of the early decline in serum T(3) concentration and serum IL-6 rise and TNF-in nonthyroidal illness syndrome induced by abdominal surgery. J Clin Endocrinol Metab. 2001;86:4198-4205.
8. Bartalena L Martino E Brandi LS et al. Lack of nocturnal serum thyrotropin surge after surgery J Clin Endocrinol Metab. 1990 70 293-296.
9. Romijn JA, Wiersinga WM. Decreased nocturnal surge of thyrotropin in nonthyroidal illness. J Clin Endocrinol Metab. 1990;70:35-42.
10. Redout EM, van der Toorn A, Zui dwijk MJ, et al. Antioxidant treatment attenuates pulmonary arterial hypertension-induced heart failure. Am J Physiol Heart Circ Physiol. 2010;298:H1038-H1047.
11. Wajner SM, Goemann IM, Bueno A L, Larsen PR, Maia AL. IL-6 promotes nonthyroidal illness syndrome by blocking thyroxine activation while promoting thyroid hormone inactivation in human cells. J Clin Invest. 2011;121:1834-1845.
12. Boelen A, Kwakkel J, Fliers E. Beyond low plasma T3: local thyroid hormone metabolism during inflammation and infection. Endocr Rev. 2011;32:670-693.
13. van der Poll T, Van Zee KJ, En dert E, et al. Interleukin-1 receptor blockade does not affect endotoxin-induced changes in plasma thyroid hormone and thyrotropin concentrations in man. J Clin Endocrinol Metab. 1995;80:1341-1346.
14. L im CF, Docter R, Visser TJ, et al. Inhibition of thyroxine transport into cultured rat hepatocytes by serum of nonuremic critically ill patients: effects of bilirubin and nonesterified fatty acids. J Clin Endocrinol Metab. 1993;76:1165-1172.
15. Gardner DF, Kaplan MM, Stanley CA, Utiger RD. Effect of triiodothyronine replacement on the metabolic and pituitary responses to starvation. N Engl J Med. 1979;300:579-584.
16. Moshang T Jr., Parks JS, Baker L, et al. Low serum triiodothyronine in patients with anorexia nervosa. J Clin Endocrinol Metab. 1975; 40:470-473.
17. Peeters RP, Wouters PJ, van Toor H, Kaptein E, Visser TJ, Van den Berghe G. Serum 3,3-,5-triiodothyronine (rT3) and 3,5,3-triiodothyronine/rT3 are prognostic markers in critically ill patients and are associated with postmortem tissue deiodinase activities. J Clin Endocrinol Metab. 2005;90:4559-4565.
18. Rothwell PM, Lawler PG. Prediction of outcome in intensive care patients using endocrine parameters. Crit Care Med. 1995;23:78-83.
19. Klemperer JD, Klein I, Gomez M, et al. Thyroid hormone treatment after coronary-artery bypass surgery. N Engl J Med. 1995;333: 1522-1527.
20. Mullis-Jansson SL, Argenziano M, Corwin S, et al. A randomized double-blind study of the effect of triiodothyronine on cardiac function and morbidity after coronary bypass surgery. J Thorac Cardiovasc Surg. 199 9;117:1128-1134.
21. Casaer MP, Mesotten D, Hermans G, et al. Early versus late parenteral nutrition in critically ill adults. N Engl J Med. 2011;365: 506-517.
22. Langouche L, Vander Perre S, Marques M, et al. Impact of early nutrient restriction during critical illness on the nonthyroidal illness syndrome and its relation with outcome: a randomized, controlled clinical study. J Clin Endocrinol Metab. 2013;98:1006-1013.
23. Mebis L, Eerdekens A, G üiza F, et al. Contribution of nutritional deficit to the pathogenesis of the nonthyroidal illness syndrome in critical illne ss: a rabbit model study. Endocrinology. 2012;153:973-984.
24. Boelen A, Boorsma J, Kwakkel J, et al. Type 3 deiodinase is highly expressed in infiltrating neutrophilic granulocytes in response to acute bacterial infection. Thyroid. 2008;18:1095-1103.
25. Van den Berghe G, de Zegher F, Veldhuis JD, et al. Thyrotrophin and prolactin release in prolonged critical illness: dynamics of spon taneous secretion and effects of growth hormone-secretagogues. Clin Endocrinol (Oxf). 1997;47:599-612.
26. Fliers E, Guldenaar SE, Wiersinga WM, Swaab DF. Decreased hypothalamic thyrotropin-relea sing hormone gene expression in patients with nonthyroidal illness. J Clin Endocrinol Metab. 1997;82: 4032-4036.
27. Bacci V, Schussler GC, Kaplan TB. The relationship between serum triiodothyronine and thyrotropin during systemic illness. J Clin Endocrinol Metab. 1982;54:1229-1235.
28. Damas P, Reuter A, Gysen P, Demonty J, Lamy M, Franchimont P. Tumor necrosis factor and interleuki n-1 serum levels during severe sepsis in humans. Crit Care Med. 1989;17:975-978.
29. Faglia G Ferrari C Beck-Peccoz P Spada A Travaglini P Ambrosi B. Reduced plasma thyrotropin respo nse to thyrotropin releasing hormone after dexamethasone administration in normal subjects Horm Metab Res. 1973 5 289-292.
30. Van den Berghe G, de Zegher F, Lauwers P. Dopamine and the sick euthyroid syndrome in critical illness. Clin Endocrinol (Oxf). 1994; 41:731-737.
31. Van den Berghe G, de Zegher F, Lauwers P. Dopamine suppresses pituitary function in infants and children. Crit Care Med. 1994;22: 1747-1753.
32. Boelen A, Kwakkel J, Thijssen-Timmer DC, Alkemade A, Fliers E, Wiersinga WM. Simultaneous changes in central and peripheral components of the hypothalamus-pituitar y-thyroid axis in lipopolysaccharide-induced acute illness in mice. J Endocrinol. 2004;182: 315-323.
33. Mebis L, Debaveye Y, Ellger B, et al. Changes in the central component of the hypothalamus-pituitary-thyroid axis in a rabbit model of prolonged critical illness. Crit Care. 2009;13:R147.
34. Alkemade A, Friesema EC, Kuiper GG, et al. Novel neuroanatomical pathways for thyroid hormone action in the human anterior pituitary. Eur J Endocrinol. 2006;154:491-500.
35. L angouche L, Princen L, Gunst J, Güiza F, Derde S, Van den Berghe G. Anterior pituitary morphology and hormone production during sustained critical illness in a rabbit model. Horm Metab Res. 2013; 45:277-282.
36. Mebis L, Paletta D, Debaveye Y, et al. Expression of thyroid hormone transporters during critical illness. Eur J Endocrinol. 2009; 161:243-250.
37. Mebis L, Langouch e L, Visser TJ, Van den Berghe G. The type II iodothyronine deiodinase is up-regulated in skeletal muscle during prolonged critical illness. J Clin Endocrinol Metab. 2007;92:3330-3333.
38. Ma SF, Xie L, Pino-Yanes M, et al. Type 2 deiodinase and host responses of sepsis and acute lung injury.AmJ Respir Cell Mol Biol. 2011;45:1203-1211.
39. Thijssen-Timmer DC, Peeters RP, Wouters P, et al. Thyroid hormone receptor isoform expression in livers of critically ill patients. Thyroid. 2007;17:105-112.
40. Van den Berghe G, Wouters P, Weekers F, et al. Reactivation of pituitary hormone release and metabolic improvement by infusion of growth hormone-releasing peptide and thyrotropin-releasing hormone in patients with protracted critical illness. J Clin Endocrinol Metab. 1999;84:1311-1323.
41. Van den Berghe G, de Zegher F, Baxter RC, et al. Neuroendocrinology of prolonged critical illness: effects of exogenous thyrotropin-releasing hormone and its combination with growth hormone secretagogues. J Clin Endocrinol Met ab. 1998;83:309-319.
42. Weekers F, Michalaki M, Coopmans W, et al. Endocrine and metabolic effects of growth hormone (GH) compared with GH-releasing peptide, thyrotropin-releasing hormone, and insulin infusion in a rabbit model of prolonged critical illness. Endocrinology. 2004; 145:205-213.
43. Van den Berghe G, Baxter RC, Weekers F, Wouters P, Bowers CY, Iranmanesh A, Veldhuis JD, Bouillon R. The combined administration of GH-releasing peptide-2 (GHRP-2), TRH and GnRH to men with prolonged critical illness evokes superior endocrine and metabolic effects compared to treatment with GHRP-2 alone. Clin Endocrinol (Oxf). 2002;56:655-669.
44. Mebis L, van den Berghe G. The hypothalamus-pituitary-thyroid axis in critical illness. Neth J Med. 2009;67:332-340.
45. Debaveye Y, Ellger B, Mebis L, et al. Tissue deiodinase activity during prolonged critical illness: effects of exogenous thyrotropinreleasing hormone and its combination with growth hormone-releasing peptide-2. Endocrinology. 2005;146:5604-5611.
46. Debaveye Y, Ellger B, Mebis L, Darras VM, Van den Berghe G. Regulation of tissue iodothyronine deiodinase activity in a model of prolonged critical illness. Thyroid. 2008;18:551-560.
47. Debaveye Y, Ellger B, Mebis L, Visser TJ, Darras VM, Van den Berghe G. Effects of substitution and high-dose thyroid hormone therapy on deiodination, sulfoconjugation, and tissue thyroid hormone levels in prolonged c ritically ill rabbits. Endocrinology. 2008; 149:4218-4228.
48. Peeters RP, van der Geyten S, Wouters PJ, et al. Tissue thyroid hormone levels in critical illness. J Clin Endocrinol Metab. 2005; 90:6498-6507.
49. Acker CG, Singh AR, Flick RP, Bernardini J, Greenberg A, Johnson JP. A trial of thyroxine in acute renal failure. Kidney Int. 2000;57: 293-298.
50. Becker RA Vaughan GM Ziegler MG et al. Hypermetabolic low triiodothyronine syndrome of burn injury Crit Care Med. 1982 10 870-875.
51. Brent GA, Hershman JM. Thyroxine therapy in patients with severe nonthyroidal illnesses and low serum thyroxine concentration. J Clin Endocrinol Metab. 1986;63:1-8.
52. Sirlak M, Yazicioglu L, Inan MB, et al. Oral thyroid hormone pretreatment in left ventricular dysfunction. Eur J Cardiothorac Surg. 2004;26:720-725.
53. Debaveye Y, Vandenbrande J, Van den Berghe G. Endocrine emergencies. In: Tubaro M, Danchin N, Filippatos G, Goldstein P, Vranckx P, Zahger D, eds. The ESC Textbook of Intensive and Acute Cardiac Care. New York: Ox ford University Press; 2011: 709-717.
54. Nicoloff JT. Thyroid storm and myxedema coma. Med Clin North Am. 1985;69:1005-1017.
55. Ringel MD. Management of hypothy roidism and hyperthyroidism in the intensive care unit. Crit Care Clin. 2001;17:59-74.
56. Escobar-Morreale HF, Obregón MJ, Escobar del Rey F, Morreale de Escobar G. Replacement therapy for hypot hyroidism with thyroxine alone does not ensure euthyroidism in all tissues, as studied in thyroidectomized rats. J Clin Invest. 1995;96:2828-2838.
57. Van den Berghe G. Endocrine aspects of critical care medicine. In: Jameson JL, De Groot LJ, eds. Endocrinology: Adult and Pediatric. St Louis, MO: WB Saunders; 2010:2084-2085.
58. Finlay WE, McKee JI. Serum cortisol levels in severely stressed patients. Lancet. 1982;1:1414-1415.
59. Munck A, Guyre PM, Holbrook NJ. Physiological functions of glucocorticoids in stress and their relation to pharmacological actions. Endocr Rev. 1984;5:25-44.
60. Starling EH. The wisdom of the body: The Harveian Oration, delivered before The Royal College of Physicians of London on St. Luke's Day, 1923. Br Med J. 1923;2:685-690.
61. Vermes I, Beishuizen A, Hampsink RM, Haanen C. Dissociation of plasma adrenocorticotropin and cortisol levels in critically ill patients: possible role of endothelin and atrial natriuretic hormone. J Clin Endocrino l Metab. 1995;80:1238-1242.
62. Boonen E, Vervenne H, Meersseman P, et al. Reduced cortisol metabolism during critical illness. N Engl J Med. 2013;368:1477-1488.
63. Bornstein SR, EngelandWC,Ehrhart-BornsteinM,HermanJP. Dissociation of ACTH and glucocorticoids. Trends Endocrinol Metab. 2008;19:175-180.
64. Vanwijngaerden YM, Wauters J, Lan gouche L, et al. Critical illness evokes elevated circulating bile acids related to altered hepatic transporter and nuclear receptor expression. Hepatology. 2011;54: 1741-1752.
65. Ackermann D, Vogt B, Escher G, et al. Inhibition of 11-hydroxysteroid dehydrogenase by bile acids in rats with cirrhosis. Hepatology. 1999;30:623-629.
66. McNeilly AD, Macfarlane DP, O'Flaherty E, et al. Bile acids modulate glucocorticoid metabolism and the hypothalamic-pituitaryadrenal axis in obstructive jaundice. J Hepatol. 2010;52:705-711.
67. Stauffer AT, Rochat MK, Dick B, Frey FJ, Od ermatt A. Chenodeoxycholic acid and deoxycholic acid inhibit 11-hydroxysteroid dehydrogenase type 2 and cause cortisol-induced transcriptional activation of the mineralocorticoid receptor. J Biol Chem. 2002; 277:26286-26292.
68. van den Akker EL, Koper JW, Joosten K, et al. Glucocorticoid receptor mRNA levels are selectively decreased in neutrophils of children with sepsis. Intensive Care Med. 2009;35:1247-1254.
69. Barquist E, Kirton O. Adrenal insufficiency in the surgical intensive care unit patient. J Trauma. 1997;42:27-31.
70. Kanczkowski W, Chatzigeorgiou A, Grossklaus S, Sprott D, Bornstein SR, Chavakis T. Role of the endothelial-derived endogenous anti-inflammatory factor Del-1 in inflammation-mediated adrenal gland dysfunction. Endocrinology. 2013;154:1181-1189.
71. Pri gent H, Maxime V, Annane D. Science review: mechanisms of impaired adrenal function in sepsis and molecular actions of glucocorticoids. Crit Care. 2004;8:243-252.
72. Annane D Sébille V TrochéG Raphaël JC Gajdos P Bellissant E. A 3-level prognostic classification in septic shock based on cortisol levels and cortisol response to corticotropin JAMA. 2000 283 1038-1045.
73. Beis huizen A, Vermes I, Hylkema BS, Haanen C. Relative eosinophilia and functional adrenal insufficiency in critically ill patients. Lancet. 1999;353:1675-1676.
74. Richards ML, Caplan RH, Wi ckus GG, Lambert PJ, Kisken WA. The rapid low-dose (1 microgram) cosyntropin test in the immediate postoperative period: results in elderly subjects after major abdominal surgery. Surgery. 1999;125:431-440.
75. Marik PE, Pastores SM, Annane D, et al. Recommendations for the diagnosis and management of corticosteroid insufficiency in critically ill adult patients: consensus statements from an international task force by the American Co llege of Critical Care Medicine. Crit Care Med. 2008;36:1937-1949.
76. Chan WL, Carrell RW, Zhou A, Read RJ. How changes in affinity of corticosteroid-binding globulin modulate free cortisol concentration. J Clin Endocrinol Metab. 2013;98:3315-3322.
77. Hamrahian AH, Oseni TS, ArafahBM.Measurements of serum free cortisol in critically ill patients. N Engl J Med. 2004;350:1629-1638.
78. Holland PC, Hancock SW, Hodge D, Thompson D, Shires S, Evans S. Degradation of albumin in meningococcal sepsis. Lancet. 2001; 357:2102-2104.
79. Pugeat M, Bonneton A, Perrot D, et al. Decreased immunoreactivity and binding activi ty of corticosteroid-binding globulin in serum in septic shock. Clin Chem. 1989;35:1675-1679.
80. Bergquist M, Nurkkala M, Rylander C, Kristiansson E, Hedensti-erna G, Lindholm C. Express ion of the glucocorticoid receptor is decreased in experimental Staphylococcus aureus sepsis. J Infect. 2013;67:574-583.
81. Guerrero J, Gatica HA, Rodriguez M, Estay R, Goecke IA. Septic se rum induces glucocorticoid resistance and modifies the expression of glucocorticoid isoforms receptors: a prospective cohort study and in vitro experimental assay. Crit Care. 2013;17:R107.
82. Indyk JA, Cand ido-Vitto C, Wolf IM, et al. Reduced glucocorticoid receptor protein expression in children with critical illness. Horm Res Paediatr. 2013;79:169-178.
83. Peeters RP, Hagendorf A, Vanhorebee k I, et al. Tissue mRNA expression of the glucocorticoid receptor and its splice variants in fatal critical illness. Clin Endocrinol (Oxf). 2009;71:145-153.
84. Siebig S, Meinel A, Rogler G, et al. Decreased cytosolic glucocorticoid receptor levels in critically ill patients. Anaesth Intensive Care. 2010;38:133-140.
85. Cohen J, Ward G, Prins J, Jones M, Venkatesh B. Variab ility of cortisol assays can confound the diagnosis of adrenal insufficiency in the critically ill population. Intensive Care Med. 2006;32:1901-1905.
86. Vassiliadi DA, Ilias I, Tzanela M, et al. Interstitial cortisol obtained by microdialysis in mechanically ventilated septic patients: correlations with total and free serum cortisol. J Crit Care. 2013;28:158-165.
87. Venkatesh B, Morgan TJ, Coh en J. Interstitium: The next diagnostic and therapeutic platform in critical illness. Crit Care Med. 2010; 38:S630-S636.
88. Chung TT, Grossman A, Clark AJ. Adrenal insufficiency. In: Jameson JL, De Groot LJ, eds. Endocrinology: Adult and Pediatric. St Louis, MO: WB Saunders; 2010;1853-1863.
89. Annane D, Sébille V, Charpentier C, et al. Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA. 2002;288:862-871.
90. Bollaert PE, Charpentier C, Levy B, Debouverie M, Audibert G, Larcan A. Reversal of late septic shock with supraphysiologic doses of hydrocortisone. Crit Care Med. 1998;26:645-650.
91. Briegel J, Forst H, Haller M, et al. Stress doses of hydrocortisone reverse hyperdynamic septic shock: a prospective, randomized, double-blind, single-center study. Crit Care Med. 1999;27:723-732.
92. Sprung CL, Annane D, Keh D, et al. Hydrocortisone therapy for patients with septic shock. N Engl J Med. 2008;358:111-124.
93. Hermans G Wilmer A Meersseman W et al. Impact of intensive insulin therapy on neuromuscular complications and ventilator dependency in the medical intensive care unit Am J Respir Crit Care Med. 2007 175 480-489.
94. Hermans G, De Jo nghe B, Bruyninckx F, Van den Berghe G. Clinical review: critical illness polyneuropathy and myopathy. Crit Care. 2008;12:238.
95. Hauer D, Weis F, Papassotiropoulos A, et al. Relati onship of a common polymorphism of the glucocorticoid receptor gene to traumatic memories and posttraumatic stress disorder in patients after intensive care therapy. Crit Care Med. 2011;39:643-650.
96. Ledderose C, Möhnle P, Limbeck E, et al. Corticosteroid resistance in sepsis is influenced by microRNA-124-induced downregulation of glucocorticoid receptor-. Crit Care Med. 2012;40:2745-2753.
97. Baker AC, Chew VW, Green TL, et al. Single nucleotide polymorphisms and type of steroid impact the functional response of the human glucocorticoid receptor. J Surg Res. 2013;180:27-34.
98. Ahrens CL, Barletta JF, Kanji S, et al. Effect of low-calorie parenteral nutrition on the incidence and severity of hyperglycemia in surgical patients: a randomized, controlled trial. Crit Care Med. 2005;33: 2507-2512.
99. Olveira G, Tapia MJ, Ocón J, et al. Parenteral nutrition-associated hyperglycemia in non-critically ill inpatients increases the risk of in-hospital mortality (multicenter study). Diabetes Care. 2013;36: 1061-1066.
100. Pasquel FJ, Smiley D, Spiegelman R, Lin E, Peng L, Umpierrez GE. Hyperglycemia is associated with increased hospital complications and mortality during parenteral nutrition. Hosp Pra ct. 2011;39: 81-88.
101. Pieracci F, Hydo L, Eachempati S, Pomp A, Shou J, Barie PS. Higher body mass index predicts need for insulin but not hyperglycemia, nosocomial infection, or death in critically ill surgical patients. Surg Infect (Larchmt). 2008;9:121-130.
102. Weiss M, Kron M, Hay B, Taenzer M, Radermacher P, Georgieff M. Which variables are associated with blood glucose levels outside the target range in surgi cal critically ill patients A retrospective observational study. Patient Saf Surg. 2011;5:5.
103. Krinsley JS. Glycemic control in the critically ill-3 domains and diabetic status means one size does not fit all! Crit Care. 2013;17: 131.
104. Falciglia M, Freyberg RW, Almenoff PL, D'Alessio DA, Render ML.Hyperglycemia-related mortality in critically ill patients varies with admission diagnosis. Crit Care Med. 2009;37:3001-3009.
105. van den Berghe G, Wouters P, Weekers F, et al. Intensive insulin therapy in critically ill patients. N Engl J Med. 2001;345:1359-1367.
106. Van den Berghe G, Wilmer A, Hermans G, et al. Intensive insulin therapy in the medical ICU. N Engl J Med. 2006;354:449-461.
107. Vlasselaers D, Milants I, Desmet L, et al. Intensive insulin therapy for patients in paediatric intensive care: a prospective, randomised controlled study. Lancet. 2009;373:547-556.
108. Mesotten D, Gielen M, Sterken C, et al. Neurocognitive development of children 4 years after critical illness and treatment with tight glucose control: a randomized c ontrolled trial. JAMA. 2012; 308:1641-1650.
109. Agus MS, Steil GM, Wypij D, et al. Tight glycemic control versus standard care after pediatric cardiac surgery. N Engl J Med. 2012; 367:1208-1219.
110. Gunst J, Derese I, Aertgeerts A, et al. Insufficient autophagy contributes to mitochondrial dysfunction, organ failure, and adverse outcome in an animal model of critical illness. Cr it Care Med. 2013;41:182-194.
111. Langouche L, Vanhorebeek I, Vlasselaers D, et al. Intensive insulin therapy protects the endothelium of critically ill patients. J Clin Invest. 2005;115:2277-2286.
112. Vanhorebeek I, De Vos R, Mesotten D, Wouters PJ, De Wolf-Peeters C, Van den Berghe G. Protection of hepatocyte mitochondrial ultrastructure and function by strict blood glucose contr ol with insulin in critically ill patients. Lancet. 2005;365:53-59.
113. Vanhorebeek I, Gunst J, Ellger B, et al. Hyperglycemic kidney damage in an animal model of prolonged critical illness. Kidney Int. 2009;76:512-520.
114. Garber AJ Moghissi ES Bransome ED Jr. et al. American College of Endocrinology position statement on inpatient diabetes and metabolic control Endocr Pract. 2004 10 77-82.
115. Umpierrez GE, Hellman R, Korytkowski MT, et al. Management of hyperglycemia in hospitalized patients in non-critical care setting: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2012;97:16-38.
116. Finfer S, Chittock DR, Su SY, et al. Intensive versus conventional glucose control in critically ill patients. N Engl J Med. 2009;360: 1283-1297.
117. Finfer S, Liu B, Chittock DR, et al. Hypoglycemia and risk of death in critically ill patients. N Engl J Med. 2012;367:1108-1118.
118. Finfer S, Billot L. Managing blood glucose in critically ill patients with or without diabetes. Crit Care. 2013;17:134.
119. Kosiborod M, Inzucchi SE, Goyal A, et al. Relationship between spontaneous and iatrogenic hypoglycemia and mortality in patients hospitalized with acute myocardial infarction. JAMA. 2009; 301:1556-1564.
120. Tin W, Brunskill G, Kelly T, Fritz S. 15-year follow-up of recurrent " hypoglycemia" in preterm infants. Pediatrics. 2012;130:e1497-e1503.
121. Suh SW, Gum ET, Hamby AM, Chan PH, Swanson RA. Hypoglycemic neuronal deat h is triggered by glucose reperfusion and activation of neuronal NADPH oxidase. J Clin Invest. 2007;117: 910-918.
122. Van den Berghe G, Wouters PJ, Bouillon R, et al. Outcome benefit of intensiv e insulin therapy in the critically ill: insulin dose versus glycemic control. Crit Care Med. 2003;31:359-366.
123. Van den Berghe G, Wilmer A, Milants I, et al. Intensive insulin therapy in mixed medical/surgical intensive care units: benefit versus harm. Diabetes. 2006;55:3151-3159.
124. Kavanagh BP, McCowen KC. Clinical practice. Glycemic control in the ICU. N Engl J Med. 2010;363:2540-2546.
125. Vanhorebeek I, Langouche L, Van den Berghe G. Endocrine aspects of acute and prolonged critical illness. Nat Clin Pract Endocrinol Metab. 2006;2:20-31.
126. Mebis L, Van den Berghe G. Thyroid axis function and dysfunction in critical illness. Best Pract Res Clin Endocrinol Metab. 2011;25: 745-757.
127. Van den Berghe G. Intensive insulin therapy in the ICU-reconciling the evidence. Nat Rev Endocrinol. 2012;8:374-378.